RS wise these guys are killing it. $6 from it's high ASO Academy Sports and Outdoors, Inc. $62.65 0.07 (+0.11%)2:59 PM 04/05/23
You can see where this is going. It's a wild concept but soon drone AI will make it's own decision when it's time to dive and say goodbye.
In a market like this it pays to look back a little bit (Time Machine again) But just April 4 look at AVAV that day -- that was on an analyst comment and that freakin stock went vertical. There was alot of pent up buying and/or shorting leaving-- something. Then that night our favorite beef eating bad boy CRamer, actually it may of been oN the morning show he tail ran this and said good things about AVAV > I think there's some smoke here... Drone sales are rolling in. WATCH-AVAV
If the economy is slowing into recession can one buy VALE Vale S.A.? if Europe is trading at all time highs and China starts firing up... maybe yes. Super Tricky chart- $15.18-0.07(-0.46%)/ 7% yield//
Nephros sees Q1 revenue $3.7M, up 69% vs. last year 07:32 NEPH "We are very pleased with first-quarter revenue, which we believe reflects the impact of recent investments in our field sales organization," said Andy Astor, President and Chief Executive Officer of Nephros. "It is noteworthy that while this quarter's revenue was enhanced by an unusually large emergency response order, our base revenue is expected to exceed $3.0 million, representing an approximate 40% increase over last year. We are also pleased to report that we expect cash flows from water filtration operations to be at least break-even for the first quarter, and we believe the strength of our business remains on track for generating consistent positive cash flows by the middle of 2023." Nephros ended the first quarter with approximately $3.8 million in cash on a consolidated basis, compared with $3.6 million as of December 31, 2022. BHVN-$12.97 $23 price target. Lead asset, BHV-7000, designed to selectively open voltage-gated potassium ion channels expressed in the central nervous system well positioned in a "highly valued neurological target." Key opinion leader feedback continues to suggest that there is a high unmet need in patients who are afflicted with treatment-refractory focal seizures and need more efficacious options that are well-tolerated After Biohaven presented preliminary safety and pharmacokinetic data from their Phase 1 healthy volunteer SAD/MAD study of BHV-7000, Piper Sandler analyst Christopher Raymond said he is "incrementally positive" on shares as he was "impressed" that the drug's safety profile holds up at doses meaningfully higher than that of key competitor XEN1101. BHV-7000 having a wider therapeutic index and the ability to achieve higher efficacy with higher doses "could be the major differentiating feature" and these "promising but preliminary" data support the drug's "potential best-in-class safety profile," according to Raymond, who has an Overweight rating and $21 price target on Biohaven shares.
Haleon plc (HLN) Was $8.17 when we began tracking)))))))) NYSE - NYSE Delayed Price. 8.63+0.14(+1.65%) At close: 04:00PM EDT 8.76+0.13(+1.52%) Pre-Market:08:57AM EDT
Nephros, Inc. (NEPH) was $1.14 and zipped to $1.31. NasdaqCM - NasdaqCM Real Time Price. 1.2400-0.0600(-4.62%) At close: 04:00PM EDT